Itraconazole: a new triazole antifungal agent.
The azole antifungal agents represent a major advance in the management of superficial and systemic fungal infections. Itraconazole appears to have a broad spectrum of in vitro activity and is the first azole antifungal agent to have activity against Aspergillus species. Itraconazole acts primarily by impairing the synthesis of ergosterol, resulting in a defective fungal cell membrane with altered permeability and function. It is effective for a wide variety of mycotic infections and some fungal meningeal infections. Most adverse effects have been relatively minor and do not lead to discontinuation of therapy.
Zuckerman
J M
JM
Division of Infectious Diseases, Medical College of Pennsylvania, Philadelphia 19129.
Tunkel
A R
AR
D001228:Aspergillosis / Q000188:drug therapy; D001759:Blastomycosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D003047:Coccidioidomycosis / Q000188:drug therapy; D003453:Cryptococcosis / Q000188:drug therapy; D004347:Drug Interactions; D006660:Histoplasmosis / Q000188:drug therapy; D006801:Humans; D017964:Itraconazole / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D009181:Mycoses / Q000188:drug therapy; D009503:Neutropenia / Q000150:complications; D013174:Sporotrichosis / Q000188:drug therapy
D017964:Itraconazole